Background: Incretin hormones (glucagon-like peptide-1 [GLP-1] and gastric inhibitory polypeptide [GIP]) may play a role in the development of glucose intolerance and hyperglycemia in patients with hyperthyroidism.
Objective: We aimed to assess both incretin levels and treatment-induced changes in incretin levels in those with hyperthyroidism.
Methods: A total of 24 subjects (12 with hyperthyroidism and 12 healthy) were enrolled in the study.